Asset
Cadefrecitinib
Lakefront Biotherapeutics American Depositary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05856448 | phase2 | completed | 2023-06-28 | 2025-10-08 | Lakefront Biotherapeutics NV | A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus |
| NCT05695950 | phase2 | completed | 2023-02-27 | 2025-10-13 | Lakefront Biotherapeutics NV | A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis |
| NCT04594928 | phase1 | completed | 2020-10-19 | 2021-05-04 | Lakefront Biotherapeutics NV | A Study Evaluating the Effects of GLPG3667 Given as an Oral Treatment for 4 Weeks in Adults With Moderate to Severe Plaque Psoriasis |
| NCT04976270 | phase1 | completed | 2021-07-20 | 2022-01-14 | Lakefront Biotherapeutics NV | A Study to Evaluate How Well Single and Multiple Doses of GLPG3667 Are Tolerated in Healthy, Adult Subjects |
| NCT04097938 | phase1 | completed | 2019-09-18 | 2020-03-04 | Lakefront Biotherapeutics NV | A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3667 |
FDA applications (0)
This company has no applications containing this asset.